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Parkinson disease (PD) is no longer considered a complex motor disorder characterized by Parkinsonism but rather a systemic
disease with variegated non-motor deﬁcits and neurological symptoms, including impaired olfaction, autonomic failure, cognitive
impairment, and psychiatric symptoms. Many of these alterations appear before or in parallel with motor deﬁcits and then
worsen with disease progression. Although there is a close relation between motor symptoms and the presence of Lewy bodies
(LBs) and neurites ﬁlled with abnormal α-synuclein, other neurological alterations are independent of the amount of α-synuclein
inclusions in neurons and neurites, thereby indicating that diﬀerent mechanisms probably converge in the degenerative process.
Involvement of the cerebral cortex that may lead to altered behaviour and cognition are related to several convergent factors
such as (a) abnormal α-synuclein and other proteins at the synapses, rather than LBs and neurites, (b) impaired dopaminergic,
noradrenergic, cholinergic and serotoninergic cortical innervation, and (c) altered neuronal function resulting from reduced
energy production and increased energy demands. These alterations appear at early stages of the disease and may precede by
years the appearance of cell loss and cortical atrophy.
1.Introduction
Parkinson disease (PD) is clinically characterized by a
complex motor disorder known as parkinsonism and is
manifested principally by resting tremor, slowness of initial
movement, rigidity, and general postural instability. These
symptoms are mainly due to the loss of dopaminergic
neurons in the substantia nigra pars compacta, leading to
reduced dopaminergic input to the striatum and accompa-
niedbyadaptiveresponsesintheinternalandexternalglobus
pallidus, subthalamus, thalamus and substantia nigra pars
reticularis. Round, hyaline neuronal cytoplasmic inclusions
called Lewy bodies (LBs) and enlarged aberrant neurites
and threads are found in the Parkinsonian substantia nigra
[1, 2]. In addition to the substantia nigra, other nuclei are
involved such as the locus ceruleus, reticular nuclei of the
brain stem, and dorsal motor nucleus of the vagus, as well
as the basal nucleus of Meynert, the amygdala and the CA2
area of the hippocampus. LBs and aberrant neurites are also
found in these locations [1–7]. Similar lesions but extended
to the cerebral neocortex are characteristic of a closely-
related disease named Dementia with Lewy bodies (DLB)
[8].PDandDLBarethereforeconsideredLewybodydiseases
(LBDs). Neuropathology and clinical aspects of DLB have
been revised in detail elsewhere [9, 10].
LBs and neurites are composed of aggregates of normal,
misfolded and truncated proteins, and ubiquitin, all of
which are stored in the cytoplasm as nondegraded by-
products of the degenerative process [11–14]. The main
component of LBs and aberrant neurites is α-synuclein
which is abnormally phosphorylated, nitrated and oxidized,
has an abnormal crystallographic structure and abnormal
solubility, and is prone to the formation of aggregates
and insoluble ﬁbrils [15–23]. For this reason, LBDs are
categorized as α-synucleinopathies.
Mutations (A53T, A30P, E46K) in the α-synuclein gene
(SNCA; PARK1) are causative of autosomal dominant PD
[24–26]. In addition, triplication or duplication of the α-
synuclein locus is associated with PD [27–30]. Together,
these observations lay bare the crucial role of α-synuclein2 Parkinson’s Disease
in the pathogenesis of a percentage of familial cases of PD.
Recent studies have shown that methylation of the human
SNCA intron 1 reduces gene expression, and inhibition of
DNA methylation activates SNCA expression. Methylation
of SNCA intron 1 is reduced in substantia nigra, putamen
and cerebral cortex in PD, suggesting activation of SNCA
in PD [31]. α-synuclein also appears to be regulated
posttranscriptionally as two microRNAs, mir-7 and mir-153,
which bind speciﬁcally to the 3
 -untranslated region of α-
synuclein and downregulate its mRNA and protein levels
[32]. The two microRNAs reduce endogenous expression of
α-synuclein [32, 33]. Whether variation in the miRNA-433
binding site of ﬁbroblast growth factor 20 confers risk for
PD by overexpression of α-synuclein [34] requires further
validation.
Mutations in other genes are also the origin of familial
and, in some cases, sporadic PD. These include parkin
(PARK2)[ 35], DJ1 (PARK7) coding for Parkinson disease
p r o t e i n7[ 36], PINK1 (PARK6) coding for PTEN-induced
putative kinase 1 [37], LRRK2 (PARK8) coding for leucine-
rich repeat kinase 2 [38, 39]a n dHTRA2 (PARK13) coding
for HtrA serine peptidase 2: HtrA2 [40]. Another gene
involved in familial PD is UCHL1 (PARK5) coding for
ubiquitin carboxyl-terminal hydrolase L1 [41]. A strong
association between galactocerebrosidase mutations and PD
has recently been reported [42]. Additonal loci associated
with autosomal or recessive PD have been described (see
[43–45]). An important point is that not all familial cases
with PD due to parkin and LRRK2 mutations have LBs,
although all of them have predominant degeneration of
the substantia nigra pars compacta (see [46], for review).
Therefore, PD cases due to parkin and LRRK2 mutations
without LBs cannot be considered as instances of LBD.
Yet mutations in PINK1 are associated with LB pathology
similar to that seen in sporadic PD [47].
2.Stages of PD-Related Pathology
Systematic study of cases with LB pathology has prompted a
stagingclassiﬁcationofPDbasedontheputativeprogression
of LB pathology from the medulla oblongata (and olfactory
bulb) to the midbrain, diencephalic nuclei, and neocortex
[48–50]). Stage 1 is characterized by LBs and neurites in the
dorsal IX/X motor nuclei and/or intermediate reticular zone;
there is also myenteric plexus involvement. Stage 2 aﬀects
the medulla oblongata and pontine tegmentum and covers
pathology of stage 1 plus lesions in the caudal raphe nuclei,
gigantocellular reticular nucleus, and ceruleus-subceruleus
complex; the olfactory bulb is also involved. Stage 3 refers
to pathology of stage 2 plus midbrain lesions, particularly
in the pars compacta of the substantia nigra. Stage 4
includes basal prosencephalon and mesocortex pathology
(cortical involvement conﬁned to the transentorhinal region
and allocortex, and CA2 plexus) in addition to lesions
in the midbrain, pons and medulla oblongata. Stage 5
extends to sensory association areas of the neocortex and
prefrontal neocortex. Stage 6 includes, in addition, lesions
in ﬁrst order sensory association areas of the neocor-
tex and premotor areas; occasionally there are also mild
changes in primary sensory areas and the primary motor
ﬁeld.
Cases with Lewy pathology in the brain stem without
clinical evidence of parkinsonism are considered premotor
PD or incidental LBD [1, 2]. Risk factor proﬁles in incidental
LBD and PD are similar thus further supporting the idea
that iLBD represents preclinical PD, arrested PD or a partial
syndrome [51].
Furthermore, several atypical cases have been reported,
the majority of them not following a clear gradient of
Lewy body pathology from the medulla oblongata to the
neocortex. LBs in the amygdala are predominant or even
unique in some cases, most of them related with Alzheimer’s
disease and Down syndrome. For this reason, amygdala-
predominant LB disease has been categorized as a distinct
entity [52]. Finally, a few cases have been reported with
predominant cortical LB pathology and discrete numbers of
LBs in the brain stem [53, 54]. Atypical cases constitute from
ﬁve to ten percent of total LBD victims [55–58].
Cumulative clinical evidence reveals that olfactory dys-
function, dysautonomia, sleep fragmentation, rapid eye
movement behaviour disorder, mood and anxiety disorders,
and depression may precede parkinsonian symptoms in
a number of patients with PD clinically characterized by
parkinsonism [59–70]. Whether these clinical symptoms
are associated with LBs in selected regions of the central,
autonomous and peripheral nervous systems is a matter of
study.
The neuropathological substrates of selected nonmotor
symptoms in PD have been examined in previous reports [7]
and will be reviewed in the following paragraphs.
3. Loss of Olfaction andthe Olfactory
Bulb and Tract in PD
α-synuclein pathology aﬀecting neurons and neurites occurs
in the olfactory bulb and related olfactory nuclei at very
early stages of cases with PD-related pathology [50, 71–75].
It also occurs in cases of AD with amygdala-predominant
LB pathology [76]. Double-labelling immunohistochemi-
cal studies have shown that dopamine- and somatostnin-
positive cells are rarely aﬀected, whereas mitral cells,
calcium-binding protein- and substance-P-positive cells are
vulnerable [77]. Olfactory bulb synucleinopathy has high
speciﬁcity and sensitivity for Lewy body diseases, and it
has been suggested that olfactory bulb biopsy might be
considered to conﬁrm diagnosis in PD [78], an indication
not approved by others [79].
The number of intracytoplasmic and neuritic α-syn-
uclein inclusions in the olfactory bulb and tract is low in the
majorityofcases,thussuggestingthatα-synucleinaggregates
as visualized in current histological preparations barely
begin to explain the severity of olfactory decline. It may be
hypothesized that as in other regions, olfactory alterations in
PDare the resultofmore complicatedsettings resulting from
several molecular deﬁcits. Although no direct information is
as yet available in PD, recent studies have yielded substantial
data about the molecular pathology of the olfactory bulb.Parkinson’s Disease 3
Despite the relatively high content of glucose-6-phosphate
dehydrogenase (G6PD), NADPH-cytochrome P450 oxidor-
eductase, glutathione reductase (GR) and NADPH-dia-
phorase (NADPH-d) in the olfactory bulb of rodents
[80], signiﬁcant changes in carbonylation and nitration
have been found in the olfactory bulbs of old mice [81].
Targets of oxidation in aged olfactory bulbs, as revealed by
redox proteomics, are aldolase 1 and ferritin heavy chain
[81]. The eﬀects of aging on oxidative stress damage in the
olfactorybulbhavebeenfurtherdemonstratedinaccelerated
senescence-prone, short-lived (SAMP) mice when compared
with accelerated senescence-resistant, longer lived (SAMR)
strains [82]. Therefore, aging in the olfactory bulb is asso-
ciated with increased oxidative stress and oxidative damage.
Whether these modiﬁcations are augmented in PD is not
known, but, needless to say, future work will help to increase
our understanding of molecular alterations, other than
those related to α-synuclein, in the olfactory bulb and tract
in PD.
Ad i ﬀerent approach has brought about interesting
results. A series of PD patients underwent [(11)C]methyl-4-
piperidinyl propionate acetylcholinesterase brain PET emis-
sion tomography and olfactory testing with the University
of Pennsylvania Smell Identiﬁcation Test. The diagnosis of
PD was conﬁrmed by [(11)C]dihydrotetrabenazine vesicular
monoaminetransportertype2PET.Cholinergicdenervation
of the limbic archicortex was a more robust determinant
of hyposmia than nigrostriatal dopaminergic denervation in
subjectswithmoderatelyseverePD[83].However,itisworth
stressing that no apparent abnormalities in the cholinergic
system appear to be present at stages 1 and 2 of Braak,
and, therefore, cholinergic denervation of the limbic cortex
is probably not the only factor accounting for olfactory
disorder in early premotor stages of PD.
Disorders of olfaction also occur in familial PD but
they appear to be more benign in certain familial cases,
linkedwithLRRK2orparkinmutations,thaninsporadicPD
[84, 85].
4. Dysautonomia and Autonomic Nervous
Systemin PD
Early studies demonstrated the presence of LBs in the
parasympathetic ganglia, sympathetic ganglia, and enteric
nervous system in PD [86, 87]. LBs are consistently found
inthehypothalamus,sympathetic(intermediodorsalnucleus
of the thoracic cord and sympathetic ganglia) and parasym-
pathetic system (dorsal vagal and sacral parasympathetic
nuclei, and peripheral parasympathetic ganglia), and enteric
plexus [88–90]. Regarding central medullary autonomic
areas, the number of catecholaminergic and serotoninergic
neurons is not signiﬁcantly reduced in PD, although raphe
neurons decline in number with disease progression [91].
Neuropathological studies in large cohorts of neurologically
unimpaired aged individuals have shown that the autonomic
nuclei of the spinal cord and the peripheral autonomic
nervous system are aﬀected early on by LB pathology [74,
92–94]. Finally, α-synuclein-immunoreactive inclusions are
seen in neurons of the Meissner’s and Auerbach’s plexuses
and in the corresponding axons projecting into the mucosa
[56, 95].
Sensitive immunohistochemical methods to detect phos-
phorylated α-synuclein have revelealed multiorgan local-
ization and gradient distribution of aberrant α-synuclein
deposits. The highest densities occurred in the spinal cord,
paraspinal sympathetic ganglia, vagus nerve, gastrointestinal
tract and endocrine organs. Within the gastrointestinal tract,
the lower esophagus and the submandibular gland had
higher numbers of inclusions than the colon and rectum
[96].
The cardiovascular autonomic system is also aﬀected
in PD, and alterations implicate both tyrosine hydroxylase-
positive (extrinsic) and negative (intrinsic) nerves of the
cardiac plexus [76, 97]. Functional studies have also
demonstrated cardiac involvement in PD. [1231] meta-
iodobenzylguanidine (MIBG) myocardial scintigraphy has
s h o w nr e d u c e dM I B Gu p t a k ei nP D[ 98–102]. Importantly,
decreased MIBG uptake precedes neuronal loss in the
sympathetic ganglia [103–105]. Interestingly, accumulation
of α-synuclein aggregates occurs in the distal axons of
the cardiac sympathetic nervous system preceding that of
neuronalsomataorneuritesintheparavertebralsympathetic
ganglia, thus indicating a centripetal degeneration of the
cardiac sympathetic nerve in PD [105]. Olfactory tests,
polysomnographic studies and MIBG myocardial scintigra-
phy in combination may be used to discover early signatures
of the disease [106]. Interestingly, cardiac sympathetic
denervation precedes nigrostriatal loss in individuals bearing
the E46K mutation in SNCA [107].
These observations point to an association between
synuclein deposits and impaired function in the autonomic
nervous system. But this does not imply a causal relationship
between these events. Several aspects are still elusive and
require further study. (i) Autonomic symptoms are not
always present in PD. (ii) LB pathology in autonomic
peripheral ganglia and plexus is not always associated with
clinical symptoms. (iii) Little is known about the nature
and composition of LBs in peripheral autonomic nervous
system. (iv) No data are available about molecular changes
preceding, or associated with, early and late stages of LB
pathology in the autonomic peripheral nervous system.
(v) Little is known about the alterations other than the
accumulation of abnormal α-synuclein that might cause
altered autonomic functions in DLBs.
5. Sleep Disorders
Sleep disorders including sleep fragmentation, REM sleep
behaviour disorders, and complex paroxysmal nocturnal
motor behavioral disorders are common in PD [108–110],
and they may precede by decades motor symptoms [111].
The neuropathological substrates are poorly understood
although aﬀected nuclei in the brain stem including the
pedunculopontine nucleus probably play key roles [112].
Theventralvisualstreamappearsinvolvedinvisuoperceptive
alterations associated with REM disorders [113]. Finally,
hypocretin (orexin) cell loss following an anterior to pos-
terior gradient has been found in the hypothalamus of PD4 Parkinson’s Disease
cases with disease progression [114, 115]. This is not clearly
accompanied by constant decrease in the expression levels
of CSF orexin [116]. Whether orexin correlates with sleep
attacks and its action is mediated by dopamine receptors 3
needs validation [117].
6. Cognitive Impairment and the Cerebral
Cortex in PD
Changes in personality and moderate or mild cognitive
debilitation are found in PD. Neuropsychiatric alterations
and cognitive decline may occur at early stages of parkinson-
ism suggesting that they are an integral part of PD from the
beginning of the disease in some patients. Characteristically,
symptoms are often subtle at the beginning and diﬃcult
to detect without neuropsychological tests, although they
become aggravated with progression of the disease. Deﬁcits
mainly aﬀect executive function including working memory
and visuospatial capacity. These are often accompanied by
anxiety and depression, and excessive daytime sleepiness
probably related with sleep disturbances (see [118, 119],
for review).
Certain studies have shown an association between
cortical LBs and cognitive impairment [120–123]. Yet other
studies have not conﬁrmed this assumption [57, 58, 124–
127]. Moreover, associated AD pathology has been suggested
as an important cofactor in the progression of cognitive
impairment in PD [58]. Additional studies have not clariﬁed
a predictive role of LBs in the occurrence of cognitive deﬁcits
[128, 129] although LB pathology correlates with visual
hallucinations when present in the medial temporal lobe and
visual areas [130, 131]. Statistical analysis reveals that α-
synucleinaggregatesinlimbicregionsarerelatedtodementia
in PD as well as to visual hallucinations when there is an
underlying dementia [132].
Neuropathlogical studies in a large series have con-
ﬁrmed that staging of LB pathology is barely applicable
to cognitive impairment and dementia. Only a percentage
of cases showed a relationship between cortical LBs and
cognitive impairment and dementia [127]. Taken together,
theseobservationsstronglyindicatethatcorticalLewybodies
are not per se causative of dementia, but rather indicators
of aggregates of pathological synuclein. Other factors are
probably more responsible of altered cognitive function
in PD.
It must be stressed that tau phosphorylation and
α-synuclein phosphorylation are increased in synaptic-
enriched fractions of frontal cortex homogenates in PD
in the absence of LBs in the same tissue samples [133].
This indicates early α-synuclein alterations at the synapse
even in cases with no cognitive impairment [133]. Recent
observations have further demonstrated the presence of
s m a l la b n o r m a la g g r e g a t e so fα-synuclein at the synapses
[134, 135]. Therefore, abnormal aggregates at the synapses
in greater numbers than large cytoplasmic and neuritic
aggregates(LBsandaberrantneurites,resp.)mayaccountfor
impaired function in PD. These are important independent
observations showing that synaptic pathology occurs in the
absence of LBs and that the most common alteration in the
cerebralcortex in PDis pathology at the synapses rather than
the presence of LBs.
It is worth stressing that altered α-synuclein may result
in altered protein-protein interactions leading to altered
synaptic function. Although these modiﬁcations are barely
understood as yet, it is worth stressing that abnormal
interactions have been reported between α-synuclein and
Rab3a, a protein involved in synaptic vesicle traﬃcking,
Rab5,aproteininvolvedindopamineendocytosis,andRab8,
a protein engaged in transport [136]. Altered interactions
have also been suggested between altered α-synuclein and
phospholipase C (PLCβ1), a signalling downstream step of
metabotropic glutamate receptors [137].
In other words, LBs per se have no direct impact on
clinical symptoms but other more subtle abnormalities
are causative of impaired cortical function. In addition to
abnormal accumulation of altered proteins at the cortical
synapses, a series of convergent approaches may help to
increase understanding of the diﬀerent factors leading to
impaired cerebral function in PD. Some of them relate
to impaired dopaminergic, noradrenergic, cholinergic and
serotoninergic innervation of the cerebral cortex; others, to
intrinsic metabolic deﬁcits.
Cognitive and executive deﬁcits have been related, in
part, to reduced dopaminergic innervation in the nigrostri-
atal and mesocortical dopaminergic systems compromising
directly and indirectly, via alteration of the basal ganglia,
prefrontal cortical function [138–142]. [18F] FDOPA uptake
is reduced in frontal association areas in later stages of
PD [143]. However, altered cognitive performance is not
clearly related with impaired dopaminergic innervations of
the cerebral cortex at early stages of the disease. PET studies
with [11C] NNC112 and [18F] FDOPA have not shown
signiﬁcant associations between D(1) receptor density in the
frontal cortex and performance at early stages of PD, in spite
of a signiﬁcant association between reduced [18F] FDOPA
uptake in the putamen and poor performance in cognitive
tests [144]. Along the same lines, attenuated dopamine
release has been observed in the dorsal caudate but not in
the medial prefrontal cortex in early PD patients [145].
Yet nondopaminergic systems are known to be damaged
in PD, including the monoaminergic cells of the locus
ceruleus,serotoninergicneuronsoftherapheandcholinergic
n e u r o n so ft h en u c l e u sb a s a l i so fM e y n e r t[ 146–149].
Cholinergic deﬁcits have been postulated as causative
of frontal dysfunction in PD [150, 151]. Recent studies
have shown early alteration of the cholinergic innervation
of the cerebral cortex in PD which increases in cases with
dementia, thus correlating impaired cholinergic innervation
and cognitive impairment [152–154].
In the same line, alteration of the serotonin transporter,
as revealed by 123I-FP-CIT SPECT, has been observed in PD
and with much more severe involvement in DLB, despite the
comparable loss of striatal dopamine transporter [155].
Besides the loss of aﬀerencies, primary impaired meta-
bolism of the cerebral cortex may be causative of intrinsic
cortical decay.
Cerebral glucose metabolism is reduced in the cerebral
cortex in PD patients suﬀering from cognitive impairmentParkinson’s Disease 5
[156]. Limited, mainly posterior, blood ﬂow reductions
have been reported in PD cases with mild cognitive deﬁcits
assessed by rCB scintigraphic study using TC-HMPAO-
SPECT [157]. Metabolic and neuroimaging observations
have recently documented decreased prefrontal and pari-
etal 18F-ﬂuorodeoxyglycose uptake in PD cases with mild
cognitive deﬁcits [158, 159] .P a r a l l e lc o n c l u s i o n sh a v eb e e n
obtained using magnetic resonance; T1-weighed images
and mean diﬀusitivity and fractional anisotropy values are
increased in the frontal cortex in PD [160, 161]. White
matter hyperintensities are more frequent in PD cases with
altered cognition than in cases with preserved cognitive
functions[162].Yetvascularabnormalitiesareverycommon
in aged patients with PD [163], and we cannot rule out
the possibility that white matter alterations are related to
associate vascular/circulatory lesions rather than to primary
lesions of PD.
A detailed discussion of molecular events leading to
intrinsic cortical deﬁciencies is provided in the following
paragraph.
7.Mitochondriaand EnergyMachinery
Failurein the Cerebral Cortex in PD
Classical studies revealed abnormalities in complex I of the
respiratory chain in the substantia nigra in sporadic PD (see
[164], for review). More recently, several genes encoding
proteins relevant to maintaining mitochondrial integrity
have been shown to be causative of familial PD [165, 166].
These data further reinforce the role of mitochondria in the
pathogenesis of PD. Interestingly, several mutant proteins
associated with familial PD are linked to mitochondria
[167]. DJ1 is localized in the mitochondria and modulates
responses to oxidative stress [168, 169]. PINK1 is a protein
kinase localized in the mitochondria in which mutations in
the kinase domain are associated with mitochondrial deﬁcits
[170]. Furthermore, PINK1 is required for mitochondrial
function as it interacts with and complements parkin [171–
173]. LRRK2 is a kinase localized in the outer mitochon-
drial membrane [174]. Finally, HtrA2 is localized in the
mitochondria and is involved in apoptosis [175]. Deﬁcits in
mitochondrial function have also been identiﬁed in patients
with DJ1, parkin and PINK1 mutations [176]. Interaction
of these diﬀerent gene products seems necessary to maintain
mitochondrial homeostasis [177–179]. Moreover, mutations
in mitochondrial DNA have also been noted in familial
parkinsonism due to PINK1 mutations [180].
These observations point to the possibility that mito-
chondrial dysfunction plays a crucial role not only in
dopaminergic neurons of the substantia nigra but also in
the whole brain. In this line, brain cortex and mitochondrial
O2 uptake and complex I activity are signiﬁcantly lower in
PD, whereas mitochondrial nitric oxide synthase activity,
cytochrome content, expression of Mn-superoxide dismu-
tase (SOD2), mitochondrial mass, and oxidative damage are
signiﬁcantly higher in the frontal cortex in PD. The decreases
in tissue and mitochondrial 02 uptake and in complex I
activity are considered the consequences of mitochondrial
oxidative damage in the cerebral cortex in PD [181, 182].
Moreover, subunits of mitochondrial complex I are oxida-
tively damaged, functionally impaired and misassembled
in PD [183]. Finally, phosphorus and proton magnetic
resonance spectroscopy conﬁrm generalized mitochondrial
dysfunction in PD [184]. It is not reckless to assume that
loss of mitochondrial function is a primary cause of energy
production decay.
Increased oxidative damage has also been detected in
the frontal cortex, in addition to that reported several
years ago in the substantia nigra, in PD [185]. Several
key proteins are targets of oxidative damage in the frontal
cortex even at very early stages of PD-related pathology,
including α-synuclein, β-synuclein and SOD2 [186, 187].
Other relevant proteins are also oxidatively damaged in
PD: UCHL1, Cu, Zn-superoxide dismutase and DJ-1 [188–
190]. In addition, increased oxidative damage of aldolase A,
enolase 1 and glyceraldehyde dehydrogenase (GAPDH), all
of them involved in glycolysis and energy metabolism, is
found in the frontal cortex in premotor stages of PD and
in established parkinsonian PD disease as well [191]. In the
same line of generalized oxidative stress and stress responses
is the observation of increased glutahione peroxidase, one
of the main antioxidant enzymes inactivating hydrogen
peroxide, in microglial cells of the gray matter and white
matter in PD and DLB [192].
Recent observations have shown abnormal lipid compo-
sition in the frontal cortex at very early stages of PD-related
pathology with signiﬁcantly increased expression levels of
the highly peroxidizable docosahexanoic acid (DHA) and
increased peroxidability index [186]. Together, these features
indicatethatmitochondrialabnormalities,alteredlipidcom-
positionandincreasedoxidativedamageofproteinsinvolved
in the cytoskeleton, neurotransmission, mitochondrial func-
tion and energy metabolism occur at early, premotor stages
of PD and persist with disease progression [193]. In the
same line, recent observations have shown impaired lipid
composition of lipid rafts with dramatic reductions in their
contentsofn-3andn-6LCPUFA,especiallydocosahexaenoic
acid (22:6-n3) and arachidonic acid (20:4n-6), and increased
saturated fatty acids (16:0 and 18:0) when compared with
control brains, thus leading to increased membrane viscosity
and, probably, to increased energy demands [194].
The term “exhausted neuron” was employed in Alz-
heimer’s disease to designate a combination of metabolic
events leading to impaired and persistent energy production
accompanied by increased energy demands that may be
detected at very early stages of disease even in cases
without overt clinical symptoms of cognitive impairment
and dementia [195]. A similar scenario also occurs, albeit
with diﬀerent targets (diﬀerent primary involvement of
respiratory chain complexes, diﬀerent lipoxidative and gly-
coxidative damage, diﬀerent alteration of membrane lipid
composition), in PD. It may be postulated that intrinsic
exhaustion of neurons plays an important role in the
subtle but inexorable progression of clinical symptoms once
thresholds of neuronal tolerance cannot longer support
energy demands.
Oxidative damage in cerebral cortex has also been re-
ported in familial cases bearing the LRRK2 mutation in6 Parkinson’s Disease
Table 1: Convergence of altered metabolic events in the cerebral
cortex in Parkinson disease.
Altered cortical innervation
(i) ↓ Dopamine (nigrostriatal and mesocortical pathways):
indirect and direct pathways
(ii) ↓ Noradrenaline (locus ceruleus)
(iii) ↓ Serotonine (raphe nuclei)
(iv) ↓ Acetylcholine (nuclei of the basal forebrain)
Synaptic pathology
(i) ↑ Tau phosphorylation in synaptic fractions
(ii) ↑ α-synuclein phosphorylation in synaptic fractions
(iii) Small α-synuclein aggregates at the synapses
Altered α-synuclein and α-synuclein interactions
(i) Oxidation and phosphorylation of α-synuclein
(ii) Abnormal synuclein interactions with
(a) rab3a: possible altered synaptic traﬃc
(b) rab5: possible altered endocytosis
(c) rab8: possible altered transport
(d) PLCβ: altered mGluR1 signalling
Altered mitochondria
(i) ↑ Mitochondrial mass
(ii) ↓ Complex I of the respiratory chain
(iii) ↓ Mitochondrial O2 uptake
(iv) Oxidative damage of subunits of mitochondrial complex I
and DJ1
(v) (altered DJ1, PINK1, LRRK2, and Htr2 in familial PD)
Increased oxidative damage
(i) ↑ Lipoxidative and glycoxidative damage of proteins and
oxidative damage of DNA
(ii) ↑ Oxidative damage of proteins linked with glycolysis and
energy metabolism
(iii) ↑ Oxidative damage of superoxide dismutase 2
(iv) ↑ Oxidative damage of β-synuclein, α-synuclein, cytoskeletal
proteins and UCHL1
Altered composition of membrane lipids in the grey matter
(i) Total homogenates
(ii) Lipid rafts: ↑ viscosity
Late, secondary events
(i) Synaptic loss
(ii) Lewy bodies and neurites
(iii) Neuronal death
the absence of apparent cognitive impairment and in the
absenceofLBsincerebralcortex[196].Thisfurthersupports
the concept that the cerebral cortex is aﬀected in PD
independently of its being associated (or not) with the
presence of LBs.
Altered metabolic events in the cerebral cortex in Parkin-
son disease are summarized in Table 1.
8.PsychiatricSymptoms and
Neuropathological Correlates
Anhedonia, apathy, anxiety, panic attacks, social phobias
and depression also occur in patients with PD even
at early premotor stages and not related to medication
[68, 197, 198]. Psychotic symptoms are frequent such as
visual and auditory hallucinations, agitated confusion, vivid
dreaming, delirium and delusions [199–203]. The molec-
ular substrates of such alterations are scarcely known but
several hypothesis have been proposed including imbalance
between serotoninergic and dopaminergic systems, cortical
cholinergic deﬁciency and overstimulation of mesocorti-
colimbic dopamine receptors [201, 203–207]. Neuropatho-
logical studies have helped little to increase understanding
of depression and psychoses although recent observations
have suggested that depression is related more to cate-
cholaminergic than serotoninergic dysfunction [208], and
that hallucinations correlate with the number of Lewy
bodies in the temporal lobe, claustrum and visual cortex
[130, 131].
Finally,aninterestingandnotfullyunderstoodparadigm
is the consequence of alterations in amygdala in PD in
spite of its constant involvement in classical PD and its
almost unique alteration in amygdala-predominant LBD.
The amygdala is activated in appetitive and emotional
learning [209, 210]. Yet decreased responsiveness is found in
the amygdala in PD in the face of fearful facial expressions,
facial, prosodic and written verbal stimuli, and decision-
making and facial emotion recognition [211–213]. Whether
these modiﬁcations are the result of impaired dopaminergic
regulation [214] or the consequence of primary pathology in
the amygdala is not known.
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